A Phase 2 interventional study of Drug: SHR0302 in Atopic Dermatitis, sponsored by Reistone Biopharma Company Limited. Completed at 23 sites in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2023-05-09.
Sponsored by Reistone Biopharma Company Limited (part of Jiangsu HengRui Medicine Co., Ltd.) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies in Dermatitis, Atopic by Jiangsu HengRui Medicine Co., Ltd. — 3 open to participants now, 5 under way, 2 of them phase 3. Dermatitis, Atopic · Jiangsu HengRui Medicine Co., Ltd..
Among the 14 studies in Dermatitis, Atopic by Jiangsu HengRui Medicine Co., Ltd., this one is the 9th largest by enrollment, is the only one that started in 2019, is one of 6 in phase 2, and was the 1st registered.
1,594 studies on the registry are indexed under Dermatitis, Atopic; 287 are open to participants now.
Browse Dermatitis, Atopic studies →3 of the 14 studies in Dermatitis, Atopic by Jiangsu HengRui Medicine Co., Ltd. are open now, in 1 country. Recruiting first, the newest first:
Guangdong Hengrui Pharmaceutical Co., Ltd · Sites in China
Ages 12–17
Guangdong Hengrui Pharmaceutical Co., Ltd · Sites in China
Ages 18–75
Chengdu Suncadia Medicine Co., Ltd. · Sites in China
Ages 18–55 · Healthy volunteers
By country, each count listing its studies:
Of the 194 Dermatitis, Atopic studies recruiting now, 83 (43%) set no upper age limit and 95 (49%) stop at 75 or younger; 94 take children under 18; 51 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 8 · Phase 3 4
First in 2019; this study’s year is marked. 1 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 105 is above the median of 82 across 1,248 interventional studies indexed under Dermatitis, Atopic.
Median enrollment 159 across the 14 interventional studies. Of the 9 that completed or were terminated, 1 (11%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Reistone Biopharma Company Limited, one of the names counted as Jiangsu HengRui Medicine Co., Ltd.. Under that name alone:
Reistone Biopharma Company Limited is the lead sponsor of 16 studies on the registry; 4 are open to participants now.
3 of the studies in Dermatitis, Atopic by Jiangsu HengRui Medicine Co., Ltd. that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07309055Phase 3Guangdong Hengrui Pharmaceutical Co., LtdA Study of SHR-1819 Injection in Adolescents With Severe Atopic Dermatitis | 2027-11 |
| NCT07698756Chengdu Suncadia Medicine Co., Ltd.A Clinical Study of HRS-8797 in Healthy Participants | 2026-12 |
| NCT07321951Guangdong Hengrui Pharmaceutical Co., LtdA Study of SHR-1819 in Patients With Moderate-to-severe Atopic Dermatitis | 2027-06 |
Add all 3 to your calendar (.ics) → With an account.
Among the 14 studies in Dermatitis, Atopic by Jiangsu HengRui Medicine Co., Ltd., from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This proposed study is a randomized, double-blind, placebo-controlled, 3-arm parallel, multicenter phase II study, designed to explore the efficacy and safety of SHR0302 treatment for patients with moderate to severe atopic dermatitis.
The study will be conducted over a 12-week treatment period. Two active doses of SHR0302 will be compared to placebo and improvement in atopic dermatitis will be assessed using the Investigator's Global Score (IGA)
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants randomized in this arm will receive dose A of SHR0302 until end of study at week 12.
Drug: Drug: SHR0302
Participants randomized in this arm will receive dose B of SHR0302 until end of study at week 12.
Drug: Drug: SHR0302
Participants randomized in this arm will receive Placebo of SHR0302 until end of study at week 12.
Drug: Drug: SHR0302
The study drug, SHR0302, is designed to block the activity of an enzyme protein called JAK-1(known as a JAK-1 inhibitor).
The Percentage of Subjects Achieving Investigator's Global Assessment (IGA) Response Which Improvement ≥ 2 From Baseline.
The IGA is a validated assessment instrument used in clinical studies to rate the severity of AD globally. IGA response was defined as IGA score of 0/1 (complete or almost complete clearance of skin lesions) with an improvement in IGA score by ≥ 2 from baseline.
Time frame: At week 12
Percentage of Czema Area and Severity Index (EASI) Change.
The EASI is a validated measure used in clinical practice and clinical trials to assess the severity and extent of atopic dermatitis (AD).
Time frame: Up to week 12
Percentage of Subjects Achieving Investigator's Global Score (IGA) Response
The IGA is a validated assessment instrument used in clinical studies to rate The IGA is a validated assessment instrument used in clinical studies to rate the severity of AD globally.
Time frame: Up to week 8
Percent of Pruritus Numerical Rating Scale (NRS) Change
The Pruritus NRS is an assessment tool that participants used to report the intensity of their pruritus during a 24-hour recall period.
Time frame: Up to week 12
| Milestone | Active Comparator: SHR0302 Dose A | Active Comparator: SHR0302 Dose B | Placebo Comparator: Placebo |
|---|---|---|---|
| Started | 35 | 35 | 35 |
| Completed | 29 | 32 | 23 |
| Not completed | 6 | 3 | 12 |
The IGA is a validated assessment instrument used in clinical studies to rate the severity of AD globally. IGA response was defined as IGA score of 0/1 (complete or almost complete clearance of skin lesions) with an improvement in IGA score by ≥ 2 from baseline.
| Participants | Active Comparator: SHR0302 Dose A | Active Comparator: SHR0302 Dose B | Placebo Comparator: Placebo |
|---|---|---|---|
| The Percentage of Subjects Achieving Investigator's Global Assessment (IGA) Response Which Improvement ≥ 2 From Baseline. | 9 | 19 | 2 |
The EASI is a validated measure used in clinical practice and clinical trials to assess the severity and extent of atopic dermatitis (AD).
Results for this outcome have not been posted.
The IGA is a validated assessment instrument used in clinical studies to rate The IGA is a validated assessment instrument used in clinical studies to rate the severity of AD globally.
Results for this outcome have not been posted.
The Pruritus NRS is an assessment tool that participants used to report the intensity of their pruritus during a 24-hour recall period.
Results for this outcome have not been posted.
Collected over 12 weeks. Non-serious events are listed at a 3% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Active Comparator: SHR0302 Dose A | 0/35 (0%) | 2/35 (5.7%) | 13/35 (37.1%) |
| Active Comparator: SHR0302 Dose B | 0/35 (0%) | 1/35 (2.9%) | 16/35 (45.7%) |
| Placebo Comparator: Placebo | 0/35 (0%) | 0/35 (0%) | 10/35 (28.6%) |
| Event | Active Comparator: SHR0302 Dose A | Active Comparator: SHR0302 Dose B | Placebo Comparator: Placebo |
|---|---|---|---|
| Dermatitis atopicSkin and subcutaneous tissue disorders | 2/35 | 1/35 | 0/35 |
| Event | Active Comparator: SHR0302 Dose A | Active Comparator: SHR0302 Dose B | Placebo Comparator: Placebo |
|---|---|---|---|
| Tri-iodothyronine free increasedInvestigations | 2/35 | 1/35 | 4/35 |
| LeukocytosisBlood and lymphatic system disorders | 3/35 | 0/35 | 0/35 |
| Transaminases increasedInvestigations | 2/35 | 1/35 | 3/35 |
| HyperlipidaemiaMetabolism and nutrition disorders | 3/35 | 2/35 | 0/35 |
| HyperuricaemiaMetabolism and nutrition disorders | 2/35 | 3/35 | 0/35 |
| Upper respiratory tract infectionInfections and infestations | 2/35 | 1/35 | 0/35 |
| FolliculitisInfections and infestations | 0/35 | 2/35 | 0/35 |
| Urinary tract infectionInfections and infestations | 0/35 | 2/35 | 0/35 |
| Blood creatine phosphokinase increasedInvestigations | 1/35 | 2/35 | 0/35 |
| Blood pressure increasedInvestigations | 0/35 | 2/35 | 0/35 |
| Age, Continuous(years) | Active Comparator: SHR0302 Dose A | Active Comparator: SHR0302 Dose B | Placebo Comparator: Placebo | Total |
|---|---|---|---|---|
| Mean | 38.5 ± 14.79 | 35.2 ± 14.75 | 30.3 ± 12.59 | 34.7 ± 14.34 |
| Sex: Female, Male(Participants) | Active Comparator: SHR0302 Dose A | Active Comparator: SHR0302 Dose B | Placebo Comparator: Placebo | Total |
|---|---|---|---|---|
| Female | 15 | 12 | 9 | 36 |
| Male | 20 | 23 | 26 | 69 |
| Ethnicity (NIH/OMB)(Participants) | Active Comparator: SHR0302 Dose A | Active Comparator: SHR0302 Dose B | Placebo Comparator: Placebo | Total |
|---|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 | 0 |
| Not Hispanic or Latino | 35 | 35 | 35 | 105 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Active Comparator: SHR0302 Dose A | Active Comparator: SHR0302 Dose B | Placebo Comparator: Placebo | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Asian | 35 | 35 | 35 | 105 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 0 |
| White | 0 | 0 | 0 | 0 |
| More than one race | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Disease duration(years) | Active Comparator: SHR0302 Dose A | Active Comparator: SHR0302 Dose B | Placebo Comparator: Placebo | Total |
|---|---|---|---|---|
| Mean | 10.91 ± 10.214 | 8.95 ± 8.468 | 8.67 ± 7.624 | 9.51 ± 8.807 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Nov 2019 to primary completion in Aug 2020, 9 months.
Results were first posted in May 2023, 2 years 8 months after primary completion.
Of 196 industry-sponsored phase 2 interventional studies under Dermatitis, Atopic, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 17. This study's 9 months is below that.
Counting every sponsor, half of 224 studies reached it within 14 months; a quarter within 10 and three quarters within 19.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ivarmacitinib
Reistone Biopharma Company Limited →